Example: marketing
NEW ZEALAND DATA SHEET - Medsafe
For children at highrisk for pneumococcal disease (such as children with sickle cell - disease, asplenia, HIV infection, chronic illness or who have othe r those
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
PUBLIC HEALTH SURVEILLANCE BULLETIN - NICD
www.nicd.ac.za1 Volume 15. Issue 2 - August 2017 SURVEILLANCE BULLETIN PUBLIC HEALTH GERMS-SA Annual surveillance report for laboratory-confirmed invasive meningococcal, pneumococcal and Haemophilus influenzae disease,
PNEUMOVAX 23 - ConnecticuT Vaccine Information …
www.ctvia.orgPNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) 7999818 4 INDICATIONS AND USAGE PNEUMOVAX 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.
Global review of the distribution of pneumococcal …
www.who.intGlobal review of the distribution of pneumococcal disease by age and region Fiona RUSSELL1 Colin SANDERSON 2 Beth TEMPLE 3 …
Pneumococcal Vaccines -- CDC answers your …
immunize.orgWe gave PCV13 then PPSV23 8 weeks later to a 66-year-old patient who is newly diagnosed with a medical condition that places him at increased risk for pneumococcal disease
Annex 2 Recommendations for the production and …
www.who.int65 E Authors 87 References 88 Appendix Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants 92
PCV13 vs PPSV23: Which to Give and When
www.medicine.wisc.eduPCV13 vs PPSV23: Which to Give and When Primary Care Case Conference Elaine Rosenblatt MSN, FNP‐BC Internal Medicine Clinic— University Station